Information  X 
Enter a valid email address

Ergomed plc (ERGO)

  Print   

Monday 25 October, 2021

Ergomed plc

Exercise of Share Options and Total Voting Rights

RNS Number : 0186Q
Ergomed plc
25 October 2021
 

 PRESS RELEASE

 

 

Exercise of Share Options and Total Voting Rights

 

 

Guildford, UK - 25 October 2021: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces that, following an exercise of share options, application has been made to AIM for the admission of 150,000 new ordinary shares of 1p each in the capital of the Company (the "New Ordinary Shares").

 

Admission to trading on AIM of the New Ordinary Shares ("Admission") is expected to occur on 27 October 2021.  Following Admission, the New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares.

 

Following Admission on 27 October 2021, the total number of ordinary shares with voting rights in issue will be 49,087,126. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

 

 

ENDS

 

Enquiries:

 

Ergomed plc

 Tel: +44 (0) 1483 402 975

Miroslav Reljanović (Executive Chairman)


Richard Barfield (Chief Financial Officer)




Numis Securities Limited (Nominated Adviser and Joint Broker)

Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Matthew O'Dowd


James Black (Broker)

 

Peel Hunt LLP (Joint Broker)  

James Steel / Dr Christopher Golden

 

 

Tel: +44 (0) 20 7418 8900



Consilium Strategic Communications

Tel: +44 (0) 20 3709 5700

Chris Gardner / Matthew Neal

[email protected]

Angela Gray








About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand and a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO). For further information, visit: http://ergomedplc.com .

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEUURBRAWURUAA

a d v e r t i s e m e n t